In generalized myasthenia gravis (gMG), argenx stands out for its established VYVGART franchise and wider investigational pipeline. Johnson & Johnson, UCB, and Amgen also have U.S.-approved gMG treatments, but they differ in target, label, and treatment approach. The evidence supports comparing portfolios and approved uses—not declaring a clinical winner or ranking companies across all autoimmune diseases.
What this comparison covers
This is a focused comparison, not a complete survey of autoimmune-drug developers. The clearest overlap in the available company disclosures is gMG, a condition for which argenx, Johnson & Johnson, UCB, and Amgen have approved treatments in the United States. Argenx’s portfolio also reaches beyond gMG, and its half-year 2026 report provides a dated view of that broader activity.
The comparison combines argenx’s report for the six months ended June 30, 2026, with competitor approval announcements from 2023 through 2025. Those are not all the same reporting date: trial stages, labels, sales, and geographic availability can change. The U.S. approvals described below should not be read as a global approval list.
How the approved gMG treatments compare
All four companies have a gMG treatment in the comparison, but the mechanisms and approved populations are not identical. The table summarizes the claims and scope in the cited company announcements; it is not a substitute for current prescribing information.
The Tool Desk
Outbyte Driver Updater FREEScan for outdated or missing drivers - takes under a minuteDriver Scan →Outbyte PC Repair FREEClear out junk files and repair common Windows errorsFree Scan →| Company and treatment | Approach | U.S. approval population in the cited announcement | What distinguishes the comparison |
|---|---|---|---|
| argenx — VYVGART (efgartigimod) | FcRn-based treatment | The 2025 FDA announcement for the self-injection prefilled syringe covers adults with AChR-positive gMG. Argenx’s 2026 half-year report lists gMG among the product’s active indications. | Multiple presentations and an expanding indication portfolio; the half-year report also lists CIDP and ITP in Japan among active indications. |
| Johnson & Johnson — IMAAVY (nipocalimab) | FcRn-blocking monoclonal antibody | U.S. approval announced April 30, 2025, for adults and children aged 12 and older who are AChR- or MuSK-antibody positive. | Shares the broad FcRn target class with efgartigimod; the cited announcement includes pediatric patients aged 12 and older and both specified antibody groups. |
| UCB — RYSTIGGO (rozanolixizumab) | FcRn-binding antibody | U.S. approval announced June 27, 2023, for adults who are AChR- or MuSK-antibody positive. | Another FcRn-based option, with an adult label in the cited announcement. Delivery, dosing, and individual suitability require review of current prescribing information. |
| Amgen — UPLIZNA (inebilizumab) | CD19-directed antibody that depletes CD19-positive B cells | FDA approval for adults with AChR- or MuSK-antibody-positive gMG, announced December 11, 2025. | Uses a B-cell-targeting approach rather than FcRn blockade. Amgen reported a 1.9-point MG-ADL difference versus placebo at week 26 in the MINT trial; that trial result is not directly comparable with results from separate studies. |
Argenx’s commercial position and broader pipeline
VYVGART has several presentations and indications
Argenx’s half-year 2026 report says VYVGART was approved in more than 30 countries, with three active indications: gMG, CIDP, and ITP in Japan. It lists three presentations—intravenous, subcutaneous, and prefilled syringe. Separately, the company’s 2025 FDA announcement describes approval of the self-injection prefilled syringe for adults with AChR-positive gMG and adults with CIDP in the United States.
The same report positioned a VYVGART SC autoinjector for launch in 2027 across approved indications. That is a company forecast stated in the report, not a completed launch.
Rank #2
Development extends beyond the marketed product
As of the report’s June 30, 2026 reporting period, argenx described efgartigimod studies in seronegative gMG, ocular MG, primary ITP, Graves’ disease, myositis, and Sjögren’s disease, among other areas. It reported positive results for the ocular MG study and gave expected timing for subsequent readouts. Those stages and expected dates reflect the company’s report at that time; they are not guarantees that a trial will read out on schedule or that a candidate will be approved.
The report also described empasiprubart, an anti-C2 program, in registrational studies for multifocal motor neuropathy and CIDP, as well as a gMG combination study with VYVGART. Other candidates named in the report include adimanebart, ARGX-121, and ARGX-109. The existence of a development program does not establish that it will succeed or become a commercial product.
Crashes, No Sound, or Screen Glitches?
Random freezes, missing sound and display glitches usually trace back to one bad driver. Find and replace yours safely.Free scan · under a minuteWindows Errors? Fix Them Before They Spread
Repair common Windows errors and clear accumulated junk for a smoother, more stable PC - no reinstall needed.Free scan · no reinstallWhat the sales figures say—and what they do not
Argenx reported VYVGART product net sales of $2.8 billion for the six months ended June 30, 2026, compared with $1.7 billion for the six months ended June 30, 2025. These are company-reported half-year figures, not full-year sales, independent market-share estimates, or a direct measure of how VYVGART compares with competitors’ revenue. The figures do indicate that VYVGART was already a substantial commercial franchise in argenx’s own reporting.
For a company or investment comparison, sales are only one piece of the picture. The disclosures summarized here do not provide a like-for-like comparison of competitor revenue, development spending, profitability, valuation, or commercial outlook. They therefore cannot support a conclusion about which company is the stronger investment.
Rank #4
How to read the clinical and label differences
Mechanism and label are useful starting points: IMAAVY, RYSTIGGO, and VYVGART are FcRn-based, while UPLIZNA targets CD19-positive B cells. The cited announcements also differ in age and antibody criteria. For an individual treatment decision, those distinctions should be checked against the current local label and discussed with a clinician; the announcements alone do not provide a complete assessment of dosing, safety, or suitability.
Do not use results from separate trials as a league table. The cited programs enrolled different populations and used different trial designs, endpoints, and follow-up. Amgen’s reported week-26 MG-ADL difference, for example, is a result versus placebo in the MINT trial—not evidence that UPLIZNA is more or less effective than another company’s treatment. The sources summarized here do not establish a head-to-head clinical winner.
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
Best Value
- Autoimmune Disease Awareness design for women, men, those battling Autoimmune Disease, warriors, caregivers, supporters, and medical professionals. Show your support and raise awareness for Autoimmune Disease
- Chronic Illness, for mom, dad, girls, boys, nurse, Lupus Awareness, Immune, Invisible Illness, Warrior, survivor, who are affected by Autoimmune Disease
- Lightweight, Classic fit, Double-needle sleeve and bottom hem
What can fairly be concluded
Within this gMG-focused comparison, argenx combines a marketed FcRn-based franchise, several VYVGART presentations, and development across multiple additional indications. Johnson & Johnson and UCB also compete in the FcRn treatment class, while Amgen brings a distinct CD19-directed approach. The evidence does not establish how argenx ranks against every company developing treatments for conditions such as rheumatoid arthritis, lupus, psoriasis, or inflammatory bowel disease, nor does it settle overall company quality or investment merit.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
